Michele Andrasik, Ph.D.

Michele Andrasik, Ph.D.

Director of Social and Behavioral Sciences and Community Engagement, HVTN

Dr. Andrasik is a clinical health psychologist working to build and enhance partnerships with marginalized communities in clinical research. She has led a robust Social and Behavioral Sciences research agenda for the HVTN for over a decade.  She has extensive experience working with communities and community organizations. Her areas of expertise include CBPR, implicit bias, historical trauma, health inequities and qualitative methods.

Sally Bock

Sally Bock

Sr. Director, Integrated Marketing, HVTN

Sally Bock has over 25 years of experience in brand marketing. She joined the CoVPN after leading the Fred Hutch marketing team. Her experience ranges from Fortune 500 companies to emerging brands, as well as across many high-impact sectors, including health care, technology (SaaS, Cloud, satellite), consumer brands, social impact, higher education, and arts & culture institutions.

Briana D. Furch, M.D., M.P.H.

Briana D. Furch, M.D., M.P.H.

Clinical Trials Physician, HVTN
Protocol Team Lead, HVTN

Dr. Furch works on HIV vaccine development and trial design, mucosal immunology in HIV prevention trials, and harm reduction at the intersection of HIV and neglected infectious disease; thereby decreasing rates of morbidity caused by preventable illness, meeting the needs of populations most at risk.

William Hahn

William Hahn

Clinical Trials Physician, HVTN
Protocol Team lead, HVTN

William Hahn is clinically trained in infectious disease. During fellowship, his research experience involved the link between the innate and adaptive immune response in preclinical models of malaria. He joined the HVTN in 2019 and has worked primarily on early-phase vaccine trials. He is the chair of CoVPN 5001, a natural history study of acute COVID infection.

Carissa Karg

Carissa Karg

Director of Site Operations, HVTN

Carissa Karg joined the HVTN in 2008 and is the Director of Site Operations.  Prior to her current role, she was a Clinical Trials Manager and the Associate Director of Site Operations at the HVTN.  She has a wealth of experience with implementation and oversight of HVTN HIV vaccine and antibody clinical trials. She has an MPH with a special interest in HIV/AIDS and other infectious diseases.

Shelly Karuna, M.D., M.P.H.

Shelly Karuna, M.D., M.P.H.

Director, Antibody Program, HVTN
Sr. Clinical Trials Physician, HVTN
Protocol Team Lead, HVTN

Dr. Karuna leads global clinical trials collaborations to advance monoclonal antibody regimens for HIV & COVID-19 prevention, treatment and cure, and to inform HIV & COVID-19 vaccine development. She guides the vision and strategic plan of the Antibody Program and serves as a resource for multi-disciplinary teams, leading a portfolio of Phase 1-3 HIV & SARS-CoV-2 preventative antibody and vaccine clinical trials through development, implementation, analysis and publication.

Laurie Rinn, M.S.P.H.

Laurie Rinn, M.S.P.H.

Director, Regulatory Affairs, HVTN

Laurie Rinn is a public health professional with more than 20 years of experience in clinical research in the non-profit and global health fields. She has worked in project management, clinic coordination, and regulatory affairs in the fields of oncology, malaria and COVID-19 and HIV vaccine research.

Vivianne Rotich, M.B.A.

Vivianne Rotich, M.B.A.

Associate Director of Finance and Contracts, HVTN

As the Associate Director of Finance and Contracts at Fred Hutch, Vivianne Rotich oversees the full cycle financial activities including clinical trials budgeting, financial reporting and management, and serves as the point of contact on financial matters.

Alison Roxby, M.D., M.Sc.

Alison Roxby, M.D., M.Sc.

Staff Physician, HVTN
Director of the Scientific Leadership Development Program, HVTN

Dr. Roxby is a physician-scientist and Associate Professor of Medicine, Global Health and Epidemiology at University of Washington. Dr. Roxby’s research focuses on HIV and STI prevention in women and strategies to prevent Covid-19 in key populations. Roxby works to expand the HVTN to include the next generation of HIV vaccine researchers, especially to ensure that HVTN investigators represent the communities that we serve.

Asa Tapley

Asa Tapley, M.D., M.Sc.

Clinical Trials Physician, HVTN
Protocol Team Lead, HVTN

Dr. Tapley is a physician-scientist who serves as a liaison between clinical research site staff and leadership based in Southern Africa, and HVTN Core based in Seattle. Dr. Tapley completed his M.D. at UCSF, M.Sc. at UC Berkeley, and Internal Medicine residency at Johns Hopkins Bayview before pursuing infectious disease training at the University of Washington. He focuses on TB, HIV, and Covid-19 research.

Manuel V. Villaran, M.D., M.S.C., M.P.H.

Manuel V. Villaran, M.D., M.S.C., M.P.H.

Clinical Trials Physician, HVTN

Dr. Villaran is a graduate of the Universidad Peruana Cayetano Heredia Medical School in Lima, Peru, received a Master of Science in International Public Health and Tropical Disease from Humboldt University Berlin, Germany and a Master of Public Health from the University of Washington. He has experience as Principal Investigator, leading operations in Peru, as well as managing health teams as part of Auna, a Peruvian healthcare holding.

Stephaun E. Wallace, Ph.D., M.S.

Stephaun E. Wallace, Ph.D., M.S.

Director of External Relations, COVID-19 Prevention Network (CoVPN) & HIV Vaccine Trials Network, HVTN

Dr. Wallace is a research epidemiologist and US Army veteran with more than two decades of experience in public health and human services (HIV/AIDS and other infectious diseases) and social justice efforts, and more than a decade of experience conducting public health research globally.